AI assistant
BOSTON SCIENTIFIC CORP — Director's Dealing 2020
Jan 6, 2020
29821_dirs_2020-01-06_d58510db-059e-4046-abd0-00fefd0cfd67.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: BOSTON SCIENTIFIC CORP (BSX)
CIK: 0000885725
Period of Report: 2020-01-03
Reporting Person: Nanavaty Maulik (SVP & Pres, Neuromodulation)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2020-01-03 | Common Stock | S | 5025.0000 | $44.7277 | Disposed | 255194.0000 | Direct |
Footnotes
F1: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan.
F2: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $44.44 to $45.02, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
F3: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available.